US Markets

Johnson & Johnson files for European approval of Ebola vaccine

Credit: REUTERS/Brendan McDermid

Johnson & Johnson said on Thursday it had filed for European approval for its experimental vaccine regimen to protect against a strain of Ebola virus that most commonly causes outbreaks of the deadly disease.

Nov 7 (Reuters) - Johnson & Johnson JNJ.N said on Thursday it had filed for European approval for its experimental vaccine regimen to protect against a strain of Ebola virus that most commonly causes outbreaks of the deadly disease.

The company said it submitted two marketing authorization applications to the European Medicines Agency (EMA) for its two-dose vaccine targeting the Zaire strain of the Ebola virus. (https://reut.rs/2Nn9y89)

The company's vaccine regimen requires two injections eight weeks apart.

Last month, Merck & Co Inc's MRK.N Ebola vaccine was recommended for approval by the EMA, in a move hailed by the World Health Organization as a "triumph for public health" that could save many lives.

(Reporting by Tamara Mathias in Bengaluru; Editing by Arun Koyyur)

((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 1208;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More